Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Perioperative Disitamab Vedotin and Tislelizumab Followed by Nephron-Sparing Surgery in High-Risk Upper Tract Urothelial Carcinoma: A Phase 2 Trial (DISTINCT-I)

NCT05912816 is registered in ClinicalTrials.gov with RenJi Hospital as lead sponsor.

NCT NCT05912816
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05912816 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Perioperative Disitamab Vedotin and Tislelizumab Followed by Nephron-Sparing Surgery in High-Risk Upper Tract Urothelial Carcinoma: A Phase 2 Trial (DISTINCT-I)
Lead sponsor
RenJi Hospital
Phase
Phase 2
Overall status
Recruiting
Start date
June 10, 2023
Completion date
December 30, 2026
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

her-2 adc, kidney preservation, pd-1antibody, upper urinary tract urothelial carcinoma